Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Breast Cancer Trial Results

  • Two Drugs that Hit One Target Improve Survival in Women with Metastatic Breast Cancer
    (Updated: 02/26/2015) - Combining two drugs that target the HER2 protein, trastuzumab (Herceptin®) and pertuzumab, with chemotherapy is a new treatment option for women with HER2-positive metastatic breast cancer, according to final results from a large clinical trial.
  • New treatment option for young women with hormone-sensitive breast cancer
    (Posted: 06/01/2014) - A drug used for treating breast cancer, known as exemestane, is more effective than a common breast cancer prevention drug, tamoxifen, in preventing breast cancer recurrence in young women who also receive post-surgical treatment to suppress ovarian function. The combined results of the Tamoxifen and Exemestane Trial and Suppression of Ovarian Function Trial were presented at the 2014 ASCO Annual Meeting in Chicago.
  • Trastuzumab Benefits Women with Locally Advanced or Inflammatory Breast Cancer
    (Posted: 03/15/2010, Updated: 04/07/2014) - Women treated with trastuzumab (Herceptin) and chemotherapy before surgery and trastuzumab again after surgery had a reduced risk of the disease recurring or progressing compared with women who received pre-surgical chemotherapy but no trastuzumab, according to a study published in the January 30, 2010, Lancet.
  • Women with Breast Cancer Micrometastases in Their Sentinel Lymph Nodes May Not Need Axillary Dissection
    (Posted: 04/26/2013) - Results from a randomized clinical trial showed that women with breast cancer and only micrometastases in their sentinel lymph nodes who received axillary lymph node dissection had more side effects but no improvement in disease-free survival compared with women who had no further lymph node surgery.
  • Ten Years of Tamoxifen Reduces Breast Cancer Recurrences, Improves Survival
    (Posted: 03/20/2013) - Taking adjuvant tamoxifen for 10 years after primary treatment leads to a greater reduction in breast cancer recurrences and deaths than taking the drug for only 5 years, according to the results of a large international clinical trial.
1 2 3 4 5  Next >